Amphastar Pharmaceuticals (AMPH) Stock Rating Upgraded by BidaskClub

Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Friday.

A number of other research firms also recently weighed in on AMPH. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 27th. BMO Capital Markets raised their price target on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the company a “market perform” rating in a research report on Friday, November 10th. Raymond James Financial downgraded Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price objective on the stock. in a report on Thursday, November 9th. Jefferies Group set a $19.00 price objective on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, October 29th. Finally, Needham & Company LLC lifted their price objective on Amphastar Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, September 27th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. Amphastar Pharmaceuticals has a consensus rating of “Hold” and an average price target of $19.50.

Amphastar Pharmaceuticals (NASDAQ AMPH) traded down $0.09 during midday trading on Friday, reaching $19.37. The company’s stock had a trading volume of 111,964 shares, compared to its average volume of 162,149. Amphastar Pharmaceuticals has a twelve month low of $12.05 and a twelve month high of $19.95. The company has a quick ratio of 1.86, a current ratio of 3.08 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $890.56, a P/E ratio of 129.13, a price-to-earnings-growth ratio of 1.36 and a beta of 1.69.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The business had revenue of $57.90 million for the quarter, compared to the consensus estimate of $57.23 million. During the same quarter last year, the business posted $0.14 earnings per share. The company’s revenue for the quarter was down 9.8% on a year-over-year basis. analysts expect that Amphastar Pharmaceuticals will post -0.03 earnings per share for the current year.

In other news, Director Stephen B. Shohet sold 7,862 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $18.37, for a total value of $144,424.94. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO William J. Peters sold 6,226 shares of Amphastar Pharmaceuticals stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $19.67, for a total value of $122,465.42. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,787 shares of company stock worth $1,359,684. Company insiders own 11.10% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Victory Capital Management Inc. increased its holdings in Amphastar Pharmaceuticals by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock valued at $100,000 after purchasing an additional 842 shares during the period. SG Americas Securities LLC purchased a new position in Amphastar Pharmaceuticals during the 2nd quarter valued at about $111,000. BNP Paribas Arbitrage SA increased its holdings in Amphastar Pharmaceuticals by 58.2% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 10,545 shares of the company’s stock valued at $188,000 after purchasing an additional 3,880 shares during the period. Municipal Employees Retirement System of Michigan increased its holdings in Amphastar Pharmaceuticals by 58.8% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 13,390 shares of the company’s stock valued at $239,000 after purchasing an additional 4,960 shares during the period. Finally, Thrivent Financial For Lutherans increased its holdings in Amphastar Pharmaceuticals by 7.2% during the 2nd quarter. Thrivent Financial For Lutherans now owns 21,610 shares of the company’s stock valued at $386,000 after purchasing an additional 1,460 shares during the period. Institutional investors own 44.14% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Amphastar Pharmaceuticals (AMPH) Stock Rating Upgraded by BidaskClub” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/21/amphastar-pharmaceuticals-amph-stock-rating-upgraded-by-bidaskclub.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply